Featured Research

from universities, journals, and other organizations

Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests

Date:
August 29, 2012
Source:
University of Colorado Denver
Summary:
Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed – but results have been inconclusive at best and at times contradictory. A new study provides an explanation why: Only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed -- but results have been inconclusive at best and at times contradictory.

A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation of why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

"The hope is that oncologists could test a patient for TS and FPGS levels and so discover if the patient should be treated with pemetrexed or if another therapy might be more appropriate," says the paper's first author, Daniel C. Christoph, MD, PhD, medical oncologist at the West German Cancer Center, working as an international postdoctoral researcher in the lab of CU Cancer Center investigator, Fred Hirsch, MD, PhD.

Pemetrexed works by inhibiting the enzyme TS, which cancer cells need in order to replicate their DNA. So it stands to reason that tumors already low in TS would be most affected by the drug -- blocking the remaining TS would effectively stop the ability of cancer cells to synthesize new DNA.

However, Christoph and colleagues tested 84 samples of mesothelioma in which patients had been treated with pemetrexed and found that low levels of TS only in combination with concurrently high levels of FPGS predicted patients' response to the drug.

The study also explained the mechanism by which FPGS increases the clinical effectiveness of pemetrexed: "High levels of FPGS allow pemetrexed to stay longer inside cells, giving the drug longer to work against TS," Christoph says. Of the samples tested, patients with low TS and high FPGS had more response to pemetrexed and longer durations of survival.

According to Christoph, the current study provides the preclinical work needed to justify exploring the predictive power of TS and FPGS in mesothelioma patients. A prospective observational study of these biomarkers could lead to their wide use in predicting patients' response to pemetrexed.


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Journal Reference:

  1. Daniel C. Christoph, Bernadette Reyna Asuncion, Celine Mascaux, Cindy Tran, Xian Lu, Murry W. Wynes, Thomas C. Gauler, Jeremias Wohlschlaeger, Dirk Theegarten, Volker Neumann, Rodrigo Hepp, Stefan Welter, Georgios Stamatis, Andrea Tannapfel, Martin Schuler, Wilfried E. Eberhardt, Fred R. Hirsch. Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012; 7 (9): 1440 DOI: 10.1097/JTO.0b013e318260deaa

Cite This Page:

University of Colorado Denver. "Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests." ScienceDaily. ScienceDaily, 29 August 2012. <www.sciencedaily.com/releases/2012/08/120829141809.htm>.
University of Colorado Denver. (2012, August 29). Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2012/08/120829141809.htm
University of Colorado Denver. "Malignant mesothelioma patients likely to benefit from drug pemetrexed identified, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/08/120829141809.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins